Neural Signatures of Memory Encoding in Schizophrenia Are Modulated by Antipsychotic Treatment.

There is no pharmacological treatment to remediate cognitive impairment in schizophrenia (SZ). It is imperative to characterize underlying pathologies of memory processing in order to effectively develop new treatments. In this longitudinal study, we combined functional magnetic resonance imaging during a memory encoding task with proton MR spectroscopy to measure hippocampal glutamate + glutamine (Glx). Seventeen SZ were scanned while unmedicated and after 6 weeks of treatment with risperidone and compared to a group of matched healthy controls (HC) scanned 6 weeks apart. Unmedicated patients showed reduced blood oxygen level dependent (BOLD) response in several regions, including the hippocampus, and greater BOLD response in regions of the default mode network (DMN) during correct memory encoding. Post hoc contrasts from significant group by time interactions indicated reduced hippocampal BOLD response at baseline with subsequent increase following treatment. Hippocampal Glx was not different between groups at baseline, but at week 6, hippocampal Glx was significantly lower in SZ compared to HC. Finally, in unmedicated SZ, higher hippocampal Glx predicted less deactivation of the BOLD response in regions of the DMN. Using 2 brain imaging modalities allowed us to concurrently investigate different mechanisms involved in memory encoding dysfunction in SZ. Hippocampal pathology during memory encoding stems from decreased hippocampal recruitment and faulty deactivation of the DMN, and hippocampal recruitment during encoding can be modulated by antipsychotic treatment. High Glx in unmedicated patients predicted less deactivation of the DMN; these results suggest a mechanism by which faulty DMN deactivation, a hallmark of pathological findings in SZ, is achieved.

Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.

Bevacizumab is widely used for treatment of high-grade gliomas and other malignancies. Because bevacizumab has been shown to be associated with neurocognitive decline, this study is designed to investigate whether prolonged treatment with bevacizumab is also associated with brain atrophy. We identified 12 high-grade glioma patients who received bevacizumab for 12 months at the first recurrence and 13 matched controls and blindly compared the volumes of the contralateral hemispheres and contralateral ventricle in these two groups at baseline and after 12 ± 2 months of the baseline scan by two independent analyses. The volumes of the contralateral hemispheres and ventricles did not differ significantly between the two groups at baseline. Whereas, in the control group the volumes of the contralateral hemisphere changed subtly from baseline to follow-up (p = 0.23), in the bevacizumab-treated group the volumes significantly decreased from baseline to follow-up (p = 0.03). There was significant increase in the contralateral ventricle volume from base line to follow-up scans in both the control group (p = 0.01) and in the bevacizumab group (p = 0.005). Both the absolute and the percentage changes of contralateral hemisphere volumes and contralateral ventricular volumes between the two patient groups were statistically significant (p < 0.05). Results of this study demonstrate prolonged treatment with bevacizumab is associated with atrophy of the contralateral brain hemisphere.

Dietary glycemic index and glucose, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein 3, and leptin levels in patients with acne.

BACKGROUND: Several isolated observations have suggested that acne can develop in groups when a high glycemic index diet is adopted. OBJECTIVE: This study was designed to examine associations among daily diet glycemic index, glycemic loads, serum insulin levels, and acne. METHODS: A total of 49 patients with acne and 42 healthy control subjects were included in the study. At the initial visit, fasting glucose, insulin, insulin-like growth factor-I, insulin-like growth factor binding protein 3, and leptin levels were measured. A voluntary self-completed questionnaire was administered and participants were asked how frequently they consumed the specified amount of food. Overall glycemic index and dietary glycemic load were calculated. RESULTS: No significant differences were observed between patients with acne and control subjects in serum glucose, insulin, leptin levels, overall glycemic index, or dietary glycemic load. LIMITATIONS: The information and data obtained from this questionnaire were limited to patients' own recollections. CONCLUSION: Results of this study indicate that dietary glycemic index, glycemic load, and insulin levels do not have a role in pathogenesis of acne in younger patients.

A link between individual differences in multisensory speech perception and eye movements.

The McGurk effect is an illusion in which visual speech information dramatically alters the perception of auditory speech. However, there is a high degree of individual variability in how frequently the illusion is perceived: some individuals almost always perceive the McGurk effect, while others rarely do. Another axis of individual variability is the pattern of eye movements make while viewing a talking face: some individuals often fixate the mouth of the talker, while others rarely do. Since the talker's mouth carries the visual speech necessary information to induce the McGurk effect, we hypothesized that individuals who frequently perceive the McGurk effect should spend more time fixating the talker's mouth. We used infrared eye tracking to study eye movements as 40 participants viewed audiovisual speech. Frequent perceivers of the McGurk effect were more likely to fixate the mouth of the talker, and there was a significant correlation between McGurk frequency and mouth looking time. The noisy encoding of disparity model of McGurk perception showed that individuals who frequently fixated the mouth had lower sensory noise and higher disparity thresholds than those who rarely fixated the mouth. Differences in eye movements when viewing the talker's face may be an important contributor to interindividual differences in multisensory speech perception.

Vergence eye movements in patients with schizophrenia.

Previous studies have shown that smooth pursuit eye movements are impaired in patients with schizophrenia. However, under normal viewing conditions, targets move not only in the frontoparallel plane but also in depth, and tracking them requires both smooth pursuit and vergence eye movements. Although previous studies in humans and non-human primates suggest that these two eye movement subsystems are relatively independent of one another, to our knowledge, there have been no prior studies of vergence tracking behavior in patients with schizophrenia. Therefore, we have investigated these eye movements in patients with schizophrenia and in healthy controls. We found that patients with schizophrenia exhibited substantially lower gains compared to healthy controls during vergence tracking at all tested speeds (e.g. 0.25 Hz vergence tracking mean gain of 0.59 vs. 0.86). Further, consistent with previous reports, patients with schizophrenia exhibited significantly lower gains than healthy controls during smooth pursuit at higher target speeds (e.g. 0.5 Hz smooth pursuit mean gain of 0.64 vs. 0.73). In addition, there was a modest (r≈0.5), but significant, correlation between smooth pursuit and vergence tracking performance in patients with schizophrenia. Our observations clearly demonstrate substantial vergence tracking deficits in patients with schizophrenia. In these patients, deficits for smooth pursuit and vergence tracking are partially correlated suggesting overlap in the central control of smooth pursuit and vergence eye movements.

Ocular convergence deficits in schizophrenia.

Individuals with schizophrenia (SZ) have been reported to exhibit a higher prevalence of convergence insufficiency (CI) than the "normal" adult population. The purpose of this study was to determine if individuals with SZ exhibit clinical signs of CI and to determine if the Convergence Insufficiency Symptom Survey (CISS) is an effective instrument for identifying CI in this population. Twenty participants with SZ and 20 healthy controls (HC) completed the study. The prevalence of CI (15%) in the SZ group was slightly higher than reported norms, but the difference was not significant. The SZ group had significantly higher scores on the CISS than the HC group, but the CISS scores did not correlate with clinical measures of CI in individuals with SZ. The only exception was that SZ patients had a significantly reduced fusional reserve as determined by Sheard's criteria. Further study is needed to determine why individuals with SZ reported symptoms associated with CI even though clinical measures did not support this diagnosis.